Onkure Therapeutics, INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and related entities have filed a Schedule 13G amendment, reporting a reduction in their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock.

Prosight Management, LP and affiliated entities have filed a Schedule 13G, reporting a combined beneficial ownership of 2.4% of OnKure Therapeutics, Inc. Class A Common Stock.

Several Biotechnology Value Funds and Mark N. Lampert have updated their beneficial ownership of OnKure Therapeutics' Class A Common Stock, reporting holdings as of May 27, 2026.

ADAR1 Capital Management and Daniel Schneeberger have reported a 6% beneficial ownership stake in OnKure Therapeutics, Inc. as of March 31, 2026.

StepStone Group and its affiliates have disclosed beneficial ownership of 2,660,612 shares, representing 6.6% of OnKure Therapeutics' Class A Common Stock.

Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have reported beneficial ownership of 6.0% of OnKure Therapeutics, Inc.'s Class A Common Stock as of March 31, 2026.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a Schedule 13G, jointly reporting beneficial ownership of 9.9% of OnKure Therapeutics, Inc. Class A common stock.

Acorn Bioventures and related entities disclose a significant beneficial ownership stake in OnKure Therapeutics, Inc., reaching up to 9.5%.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.87% beneficial ownership in OnKure Therapeutics Inc. following an internal realignment.

Prosight Management, along with affiliated funds and its sole manager, W. Lawrence Hawkins, has disclosed a collective 5.8% beneficial ownership in OnKure Therapeutics, Inc.

Cantor Fitzgerald and its affiliates have reported a 5.2% beneficial ownership stake in OnKure Therapeutics Inc., totaling 669,539 shares of Class A Common Stock.

Samsara BioCapital and its affiliates have reported zero beneficial ownership in OnKure Therapeutics, Inc. Class A Common Stock as of June 30, 2025.

Perceptive Advisors and affiliates report 0% beneficial ownership in OnKure Therapeutics, Inc., indicating a full divestment of their previously held stake.

Highbridge Capital Management, LLC has disclosed a 5.2% beneficial ownership stake in OnKure Therapeutics, Inc.'s Class A Common Stock.

Shay Capital LLC and Shay Capital Holdings LLC have jointly reported a passive beneficial ownership of 6.3% in OnKure Therapeutics, Inc.'s Class A Common Stock.

Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, indicating they no longer beneficially own any Class A Common Stock of OnKure Therapeutics, Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 4.14% passive beneficial ownership stake in Onkure Therapeutics, Inc. as of December 31, 2024.

Highbridge Capital Management, LLC has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.2% of OnKure Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.

Lundbeckfond Invest A/S and its Chief Executive Officer, Lene Skole, have jointly filed an amended Schedule 13G, reporting beneficial ownership of 1.6% of OnKure Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.

The Vanguard Group, a major investment adviser, has reported a beneficial ownership of 5.58% in OnKure Therapeutics Inc.'s Common Stock as of December 31, 2024.